---
figid: PMC11654217__40779_2024_586_Fig5_HTML
figtitle: Impact of natural compounds targeting PD-1/PD-L1 on various signaling pathways
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11654217
filename: 40779_2024_586_Fig5_HTML.jpg
figlink: /pmc/articles/PMC11654217/figure/F5/
number: F5
caption: Impact of natural compounds targeting PD-1/PD-L1 on various signaling pathways.
  AMP adenosine monophosphate, ATP adenosine triphosphate, ERK extracellular signal-related
  kinases, HIF-1α hypoxia-inducible factor 1-α, IFN-γ interferon-γ, JAK Janus kinase,
  KRAS Kirsten rat sarcoma viral oncogene homologue, mTOR mammalian target of rapamycin,
  NF-κB nuclear factor-κB, PD-1 programmed cell death protein 1, PD-L1 programmed
  cell death ligand 1, RTK receptor tyrosine kinase, STAT signal transducer and activator
  of transcription, Syk spleen associated tyrosine kinase, TLR Toll-like receptors,
  GPX glutathione peroxidase, PTEN phosphatase and TENsin homolog deleted on chromosome
  10, PI3K phosphoinositide 3-kinase, TSC tuberous sclerosis complex, MKK mitogen-activated
  protein kinase, MAPK mitogen-activated protein kinase, HSP27 heat shock protein
  27, GM-CSF granulocyte–macrophage colony-stimulating factor, TGF transforming growth
  factor, IL interleukin, CD cluster of differentiation, TCR T cell receptor, PPi
  protein protein interactions, E enzyme, EGCG epigallocatechin gallate, IκB inhibitor
  of nuclear factor-κB, IKK inhibitor of nuclear factor-κB kinase, Rheb Ras homolog
  enriched in brain, VEGF vascular endothelial growth factor, Src Src kinase, Sck
  C-terminal Src kinase, VRAP VEGF receptor associated protein
papertitle: Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by
  bioactive natural compounds for cancer immunotherapy
reftext: Yogesh Godiyal, et al. Mil Med Res. 2024;11(NA).
year: '2024'
doi: 10.1186/s40779-024-00586-9
journal_title: Military Medical Research
journal_nlm_ta: Mil Med Res
publisher_name: BMC
keywords: Cancer | PD-1/PD-L1 | Crosstalk | Natural compounds | Therapeutic targets
automl_pathway: 0.9730899
figid_alias: PMC11654217__F5
figtype: Figure
redirect_from: /figures/PMC11654217__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11654217__40779_2024_586_Fig5_HTML.html
  '@type': Dataset
  description: Impact of natural compounds targeting PD-1/PD-L1 on various signaling
    pathways. AMP adenosine monophosphate, ATP adenosine triphosphate, ERK extracellular
    signal-related kinases, HIF-1α hypoxia-inducible factor 1-α, IFN-γ interferon-γ,
    JAK Janus kinase, KRAS Kirsten rat sarcoma viral oncogene homologue, mTOR mammalian
    target of rapamycin, NF-κB nuclear factor-κB, PD-1 programmed cell death protein
    1, PD-L1 programmed cell death ligand 1, RTK receptor tyrosine kinase, STAT signal
    transducer and activator of transcription, Syk spleen associated tyrosine kinase,
    TLR Toll-like receptors, GPX glutathione peroxidase, PTEN phosphatase and TENsin
    homolog deleted on chromosome 10, PI3K phosphoinositide 3-kinase, TSC tuberous
    sclerosis complex, MKK mitogen-activated protein kinase, MAPK mitogen-activated
    protein kinase, HSP27 heat shock protein 27, GM-CSF granulocyte–macrophage colony-stimulating
    factor, TGF transforming growth factor, IL interleukin, CD cluster of differentiation,
    TCR T cell receptor, PPi protein protein interactions, E enzyme, EGCG epigallocatechin
    gallate, IκB inhibitor of nuclear factor-κB, IKK inhibitor of nuclear factor-κB
    kinase, Rheb Ras homolog enriched in brain, VEGF vascular endothelial growth factor,
    Src Src kinase, Sck C-terminal Src kinase, VRAP VEGF receptor associated protein
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HIF1A
  - GPX4
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PTEN
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - SRC
  - FGR
  - FYN
  - YES1
  - SHC2
  - SH2D2A
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - CSF2
  - TGFB1
  - TGFB2
  - TGFB3
  - IL1B
  - IL6
  - CXCL8
  - IL10
  - HSPB1
  - HSPB2
  - KRAS
  - NRAS
  - CD274
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - CD4
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - IKBKG
  - CHUK
  - IKBKB
  - IKBKE
  - TBK1
  - NFKB1
  - REL
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - APRT
  - MFAP1
  - ATP8A2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - Evodiamine
  - Polydatin
  - Hesperidin
  - Apigenin
  - Berberine
  - AMP
  - ATP
  - EGCG
  - proteins
  - Myricetin
  - Gallic acid
  - Cancer
---
